{
    "symbol": "PSNL",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-23 23:36:06",
    "content": " For example, any statements regarding trends and expectations for our financial performance this year and longer term, cash runway, revenue expectations and timing, new orders, products, services, technology, the timing of data publications, clinical and regulatory milestones, the outcome and timing of reimbursement decisions, expectations for existing and future collaboration activities, cost expectations and our market opportunities, business outlook. But in short, our in-house commercial efforts in 2023 will be focused where our MRD offering shines most for detecting cancer recurrence at the earliest possible time, longer term with a broad utility of our technology when new partner and other cancer indications giving us access to additional pieces of the entire market, which could become more than $30 billion over time. Also, it allows us to be even more strategic in providing compelling products and at the highest level of service to key biopharma partners to drive clinical trial success, and that's an engine to power personalized cancer vaccine development, as evidenced by our recent announcement of the extension of our partnership with Moderna. Total company revenue for the fourth quarter of 2022 was $16.7 million and decreased 90% compared with the same period of the prior year, which was expected due to the decline in VA MVP revenue. For the full year of 2023, we expect total Company revenue to be in the range of $68 million to $72 million with oncology revenue from pharma, enterprise sales and other customers to be in the range of $59 million to $63 million."
}